BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31311769)

  • 1. Dormant origin signaling during unperturbed replication.
    Moiseeva TN; Bakkenist CJ
    DNA Repair (Amst); 2019 Sep; 81():102655. PubMed ID: 31311769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR-Chk1 activation mitigates replication stress caused by mismatch repair-dependent processing of DNA damage.
    Gupta D; Lin B; Cowan A; Heinen CD
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1523-1528. PubMed ID: 29378956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic treatment with ATR and CHK1 inhibitors does not substantially increase the mutational burden of human cells.
    Casimir L; Zimmer S; Racine-Brassard F; Goudreau F; Jacques PÉ; Maréchal A
    Mutat Res; 2023; 827():111834. PubMed ID: 37531716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CST in maintaining genome stability: Beyond telomeres.
    Lyu X; Sang PB; Chai W
    DNA Repair (Amst); 2021 Jun; 102():103104. PubMed ID: 33780718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
    Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
    Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.
    Buisson R; Boisvert JL; Benes CH; Zou L
    Mol Cell; 2015 Sep; 59(6):1011-24. PubMed ID: 26365377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatial organization and functions of Chk1 activation by TopBP1 biomolecular condensates.
    Egger T; Morano L; Blanchard MP; Basbous J; Constantinou A
    Cell Rep; 2024 Apr; 43(4):114064. PubMed ID: 38578830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZNF827 is a single-stranded DNA binding protein that regulates the ATR-CHK1 DNA damage response pathway.
    Yang SF; Nelson CB; Wells JK; Fernando M; Lu R; Allen JAM; Malloy L; Lamm N; Murphy VJ; Mackay JP; Deans AJ; Cesare AJ; Sobinoff AP; Pickett HA
    Nat Commun; 2024 Mar; 15(1):2210. PubMed ID: 38472229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage response curtails detrimental replication stress and chromosomal instability induced by the dietary carcinogen PhIP.
    Mimmler M; Peter S; Kraus A; Stroh S; Nikolova T; Seiwert N; Hasselwander S; Neitzel C; Haub J; Monien BH; Nicken P; Steinberg P; Shay JW; Kaina B; Fahrer J
    Nucleic Acids Res; 2016 Dec; 44(21):10259-10276. PubMed ID: 27599846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dormant origins as a built-in safeguard in eukaryotic DNA replication against genome instability and disease development.
    Shima N; Pederson KD
    DNA Repair (Amst); 2017 Aug; 56():166-173. PubMed ID: 28641940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
    Qiu Z; Fa P; Liu T; Prasad CB; Ma S; Hong Z; Chan ER; Wang H; Li Z; He K; Wang QE; Williams TM; Yan C; Sizemore ST; Narla G; Zhang J
    Cancer Res; 2020 Aug; 80(16):3305-3318. PubMed ID: 32522823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.
    Khamidullina AI; Abramenko YE; Bruter AV; Tatarskiy VV
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.
    Green AM; Budagyan K; Hayer KE; Reed MA; Savani MR; Wertheim GB; Weitzman MD
    Cancer Res; 2017 Sep; 77(17):4579-4588. PubMed ID: 28655787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNF4 sustains Myc-driven tumorigenesis by facilitating DNA replication.
    Her J; Zheng H; Bunting SF
    J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38530355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A local ATR-dependent checkpoint pathway is activated by a site-specific replication fork block in human cells.
    Ahmed-Seghir S; Jalan M; Grimsley HE; Sharma A; Twayana S; Kosiyatrakul ST; Thompson C; Schildkraut CL; Powell SN
    Elife; 2023 Aug; 12():. PubMed ID: 37647215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide identification of replication fork stalling/pausing sites and the interplay between RNA Pol II transcription and DNA replication progression.
    Rojas P; Wang J; Guglielmi G; Sadurnì MM; Pavlou L; Leung GHD; Rajagopal V; Spill F; Saponaro M
    Genome Biol; 2024 May; 25(1):126. PubMed ID: 38773641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP1 UFMylation ensures the stability of stalled replication forks.
    Gong Y; Wang Z; Zong W; Shi R; Sun W; Wang S; Peng B; Takeda S; Wang ZQ; Xu X
    Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2322520121. PubMed ID: 38657044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA hypomethylation activates Cdk4/6 and Atr to induce DNA replication and cell cycle arrest to constrain liver outgrowth in zebrafish.
    Madakashira BP; Magnani E; Ranjan S; Sadler KC
    Nucleic Acids Res; 2024 Apr; 52(6):3069-3087. PubMed ID: 38321933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A consensus set of genetic vulnerabilities to ATR inhibition.
    Hustedt N; Álvarez-Quilón A; McEwan A; Yuan JY; Cho T; Koob L; Hart T; Durocher D
    Open Biol; 2019 Sep; 9(9):190156. PubMed ID: 31506018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.